EMA Authorised: Vpriv (velaglucerase alfa) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

The EMA authorises Vpriv (velaglucerase alfa) for Gaucher disease under accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• VPRIV (VELAGLUCERASE ALFA)

Snippet

Status: Authorised. Therapeutic area: Gaucher Disease. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 24/08/2026. Accelerated assessment